CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, open-label, 1-sequence crossover drug-drug-interaction study in 16
healthy male subjects to assess the effect of single and multiple doses of CKD-506 on the
single-dose PK of oral midazolam. Midazolam will be used as a cytochrome P450 (CYP)3A4
substrate in this study.